M&As this week: Merck KGaA, Genius Lead, Sanofi
German science and technology company Merck KGaA plans to acquire Canadian hydrogel membrane products provider Natrix Separations.
The acquisition strengthens Merck’s mAb and vaccine manufacturing capabilities.
Healthcare services provider Genius Lead plans to acquire 11% stake in pharmaceutical product developer Rui Kang Pharmaceutical Group Investments from Chinese pharmaceutical distributor New Ray Medicine International Holding for HK$44.21m ($5.64m).
Both Genius Lead and Rui Kang are based in Hong Kong.
Sanofi has announced the acquisition of US-based biotechnology company Protein Sciences for $750m.
The acquisition will enable the French pharmaceutical company to expand its influenza vaccine portfolio.
Chinese biotechnology company Guangdong VTR BioTech has announced the acquisition of a 15.2% stake in a biotechnology company based in Hunan for CNY38.1m ($5.74m).
The transaction increases Guangdong VTR Bio-Tech’s stake in the entity from 75% to 90.2%.